PeptideFactSheetsAn independent reference
Menu
Plain-English comparison

Next-generation metabolic peptides: beyond GLP-1 alone

How amylin analogs and glucagon-containing co-agonists differ in targets, trial maturity, liver research, weight evidence, and FDA status.

Published by PeptideFactSheets. Sources and methods · Research reporting, not clinical review.

Overview

The next metabolic wave is not one drug class. Pramlintide and cagrilintide target amylin biology; retatrutide combines GLP-1, GIP, and glucagon activity; survodutide and pemvidutide combine GLP-1 and glucagon signaling.

Pramlintide received a narrow Symlin diabetes approval, but FDA now lists its U.S. products as discontinued from marketing. The other candidates remain investigational even when large or positive trials exist. Combination results, especially CagriSema, cannot be assigned entirely to one component.

Side-by-side comparison

Pramlintide
DiscontinuedStrong human evidence for approved uses

Studied for

Glucose control with mealtime insulin · Satiety and food intake · Obesity and weight outcomes

Cagrilintide
In clinical trialsModerate human evidence

Studied for

Obesity and overweight · Type 2 diabetes · Blood pressure and cardiometabolic markers

Retatrutide
In clinical trialsModerate human evidence

Studied for

Obesity and overweight · Type 2 diabetes · Cardiovascular and kidney outcomes

Survodutide
In clinical trialsModerate human evidence

Studied for

Obesity · Metabolic dysfunction-associated steatohepatitis · Liver fat and fibrosis

Pemvidutide
In clinical trialsEarly human evidence

Studied for

MASH and MASLD · Liver fat · Obesity

Approved versus investigational

An FDA approval means the agency reviewed evidence for a specific product, population, and use. It does not validate other molecules in the same family or uses outside the label. “In Phase 3” still means investigational.

Research areas

  • Obesity and chronic weight management
  • Type 2 diabetes and glucose control
  • MASH, liver fat, and fibrosis
  • Amylin, glucagon, GLP-1, and GIP pathway combinations

Risks

  • A Phase 3 result or accepted trial endpoint is not an FDA approval.
  • Weight, liver-fat imaging, MASH resolution, and fibrosis are different outcomes.
  • Gastrointestinal tolerability, discontinuation, and long-term clinical outcomes can materially change the benefit-risk picture.

Open questions

  • Which investigational products will receive approval and for which exact populations
  • Long-term cardiovascular, liver, gallbladder, pancreatic, and metabolic outcomes
  • How much benefit and harm each receptor target contributes

Questions to ask a healthcare professional

1. Is the evidence for the peptide alone or a fixed combination?

2. Was the primary endpoint weight, liver fat, biopsy, fibrosis, or a clinical event?

3. Is the product approved for this exact use?

4. How did discontinuation and incomplete treatment affect the result?

Summary

Next-generation metabolic peptides are diversifying beyond GLP-1, but receptor count is not a ranking system. Approval, endpoint, population, tolerability, and long-term outcomes matter more than mechanistic novelty.

CompareGLP-1 peptides comparedHow semaglutide, tirzepatide, liraglutide, and investigational retatrutide differ in targets, evidence, and approval status.ComparePeptides for weight management: approved versus experimentalA status-first look at approved medicines and experimental peptides discussed for body weight.CompareGLP-1 peptides in Parkinson researchWhat the positive LIXIPARK trial and negative exenatide Phase 3 study say about GLP-1 neuroprotection claims.

Sources

  1. fdaFDA prescribing information: Symlin

    Historical product-specific diabetes labeling and the severe-hypoglycemia boxed warning.

  2. fdaFDA Symlin application and marketing status

    FDA lists the Symlin presentations as discontinued; marketing status alone does not establish an approval withdrawal.

  3. pubmedREDEFINE 1 cagrilintide-semaglutide trial

    Phase 3 evidence including combination and individual-component groups.

  4. pubmedSurvodutide Phase 2 obesity trial

    Controlled dual glucagon/GLP-1 obesity evidence.

  5. pubmedPemvidutide IMPACT MASH trial

    Mid-stage biopsy evidence and remaining fibrosis uncertainty.